Metric Snapshot
- Latest value
- -26%
- Coverage range
- 31 Dec 2015 - 31 Dec 2025
- Fact rows
- 51
Financial Metric Page
Spyre Therapeutics, Inc.: Return On Assets
Latest period: Q4 2025. Period end: 31 Dec 2025. Units: %. Frequency: quarterly and annual.
Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
What This Metric Tells You
- Shows the reported level of return on assets over 31 Dec 2015 - 31 Dec 2025.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 51 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on 10-Q / 10-K XBRL facts.
Metric Details
- Metric
- Return On Assets (ROA)
- Taxonomy
- ratio
- Units tracked
- %
- Frequency coverage
- quarterly and annual
- History range
- 31 Dec 2015 - 31 Dec 2025
- Facts on this page
- 51
- Description
- Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Return On Assets, Quarterly (%)
Return On Assets, YoY Quarterly Change (%)
Return On Assets, Annual (%)
Return On Assets, YoY Annual Change (%)
Spyre Therapeutics, Inc. Quarterly Return On Assets (%)
| Period | Value | YoY Chg | Change % | Start Date | End Date |
|---|---|---|---|---|---|
| Q4 2025 | -26% | +17% | +39% | 01 Oct 2025 | 31 Dec 2025 |
| Q3 2025 | -27% | +24% | +47% | 01 Jul 2025 | 30 Sep 2025 |
| Q2 2025 | -39% | +12% | +23% | 01 Apr 2025 | 30 Jun 2025 |
| Q1 2025 | -41% | +73% | +64% | 01 Jan 2025 | 31 Mar 2025 |
| Q4 2024 | -43% | +118% | +73% | 01 Oct 2024 | 31 Dec 2024 |
| Q3 2024 | -51% | +154% | +75% | 01 Jul 2024 | 30 Sep 2024 |
| Q2 2024 | -51% | +187% | +79% | 01 Apr 2024 | 30 Jun 2024 |
| Q1 2024 | -114% | -17% | -18% | 01 Jan 2024 | 31 Mar 2024 |
| Q4 2023 | -160% | -65% | -69% | 01 Oct 2023 | 31 Dec 2023 |
| Q3 2023 | -205% | -118% | -135% | 01 Jul 2023 | 30 Sep 2023 |
| Q2 2023 | -238% | -156% | -191% | 01 Apr 2023 | 30 Jun 2023 |
| Q1 2023 | -97% | -35% | -57% | 01 Jan 2023 | 31 Mar 2023 |
| Q4 2022 | -95% | -47% | -99% | 01 Oct 2022 | 31 Dec 2022 |
| Q3 2022 | -87% | -42% | -93% | 01 Jul 2022 | 30 Sep 2022 |
| Q2 2022 | -82% | -40% | -95% | 01 Apr 2022 | 30 Jun 2022 |
| Q1 2022 | -61% | -12% | -25% | 01 Jan 2022 | 31 Mar 2022 |
| Q4 2021 | -48% | +10% | +18% | 01 Oct 2021 | 31 Dec 2021 |
| Q3 2021 | -45% | +22% | +32% | 01 Jul 2021 | 30 Sep 2021 |
| Q2 2021 | -42% | +37% | +47% | 01 Apr 2021 | 30 Jun 2021 |
| Q1 2021 | -49% | +38% | +44% | 01 Jan 2021 | 31 Mar 2021 |
| Q4 2020 | -58% | +15% | +20% | 01 Oct 2020 | 31 Dec 2020 |
| Q3 2020 | -67% | +0.74% | +1.1% | 01 Jul 2020 | 30 Sep 2020 |
| Q2 2020 | -79% | -16% | -26% | 01 Apr 2020 | 30 Jun 2020 |
| Q1 2020 | -87% | -28% | -46% | 01 Jan 2020 | 31 Mar 2020 |
| Q4 2019 | -73% | -9.2% | -14% | 01 Oct 2019 | 31 Dec 2019 |
| Q3 2019 | -68% | -12% | -21% | 01 Jul 2019 | 30 Sep 2019 |
| Q2 2019 | -63% | -11% | -21% | 01 Apr 2019 | 30 Jun 2019 |
| Q1 2019 | -60% | -9.9% | -20% | 01 Jan 2019 | 31 Mar 2019 |
| Q4 2018 | -64% | -19% | -43% | 01 Oct 2018 | 31 Dec 2018 |
| Q3 2018 | -56% | -15% | -36% | 01 Jul 2018 | 30 Sep 2018 |
| Q2 2018 | -52% | -15% | -41% | 01 Apr 2018 | 30 Jun 2018 |
| Q1 2018 | -50% | -16% | -48% | 01 Jan 2018 | 31 Mar 2018 |
| Q4 2017 | -44% | -10% | -29% | 01 Oct 2017 | 31 Dec 2017 |
| Q3 2017 | -41% | -4.8% | -13% | 01 Jul 2017 | 30 Sep 2017 |
| Q2 2017 | -37% | -14% | -64% | 01 Apr 2017 | 30 Jun 2017 |
| Q1 2017 | -34% | +3.9% | +10% | 01 Jan 2017 | 31 Mar 2017 |
| Q4 2016 | -34% | -5.2% | -18% | 01 Oct 2016 | 31 Dec 2016 |
| Q3 2016 | -36% | 01 Jul 2016 | 30 Sep 2016 | ||
| Q2 2016 | -22% | 01 Apr 2016 | 30 Jun 2016 | ||
| Q1 2016 | -38% | 01 Jan 2016 | 31 Mar 2016 | ||
| Q4 2015 | -29% | 01 Oct 2015 | 31 Dec 2015 |
Spyre Therapeutics, Inc. Annual Return On Assets (%)
| Period | Value | YoY Chg | Change % | Start Date | End Date |
|---|---|---|---|---|---|
| 2025 | -26% | +17% | +39% | 01 Jan 2025 | 31 Dec 2025 |
| 2024 | -43% | +118% | +73% | 01 Jan 2024 | 31 Dec 2024 |
| 2023 | -160% | -65% | -69% | 01 Jan 2023 | 31 Dec 2023 |
| 2022 | -95% | -47% | -99% | 01 Jan 2022 | 31 Dec 2022 |
| 2021 | -48% | +10% | +18% | 01 Jan 2021 | 31 Dec 2021 |
| 2020 | -58% | +15% | +20% | 01 Jan 2020 | 31 Dec 2020 |
| 2019 | -73% | -9.2% | -14% | 01 Jan 2019 | 31 Dec 2019 |
| 2018 | -64% | -19% | -43% | 01 Jan 2018 | 31 Dec 2018 |
| 2017 | -44% | -10% | -29% | 01 Jan 2017 | 31 Dec 2017 |
| 2016 | -34% | 01 Jan 2016 | 31 Dec 2016 |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.